Roth Capital analyst Jonathan Aschoff lowered the firm’s price target on Cellectar Biosciences (CLRB) to $11 from $14 and keeps a Buy rating on the shares. Cellectar Biosciences reported positive 12-month Phase 2 data for iopofosine I 131 in Waldenstrom macroglobulinemia, demonstrating durable responses across patient groups and supporting the potential for an accelerated approval filing ahead of a planned Phase 3 initiation in Q4, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLRB:
- Cellectar Biosciences reports CLOVER WaM trial achieves primary endpoint
- Cellectar Therapeutics: Advancing Targeted Radiotherapeutics with Clear Clinical Catalysts Supporting a Buy Rating and $10 Price Target
- Cellectar Biosciences enrolls first patient in CLR 121125 trial
- Cellectar Biosciences upgraded to Buy from Hold at Maxim
- Cellectar Biosciences Charts Risky Path to Approvals